Brokerages Set Progenics Pharmaceuticals, Inc. (PGNX) PT at $13.33

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has been assigned a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $11.63.

A number of equities analysts have recently commented on PGNX shares. Zacks Investment Research upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 25th. Needham & Company LLC lowered shares of Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating and cut their price objective for the company from $16.00 to $12.00 in a research report on Thursday, September 13th. BidaskClub lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 16th. Finally, ValuEngine lowered shares of Progenics Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, September 13th.

Institutional investors have recently made changes to their positions in the business. Creative Planning lifted its position in Progenics Pharmaceuticals by 23.9% during the third quarter. Creative Planning now owns 258,600 shares of the biotechnology company’s stock valued at $1,621,000 after purchasing an additional 49,890 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Progenics Pharmaceuticals by 2.3% during the second quarter. Bank of New York Mellon Corp now owns 1,062,981 shares of the biotechnology company’s stock valued at $8,546,000 after purchasing an additional 24,073 shares during the last quarter. Trexquant Investment LP bought a new stake in Progenics Pharmaceuticals during the second quarter valued at approximately $281,000. Employees Retirement System of Texas lifted its position in Progenics Pharmaceuticals by 21.9% during the second quarter. Employees Retirement System of Texas now owns 139,000 shares of the biotechnology company’s stock valued at $1,118,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Progenics Pharmaceuticals by 6.8% during the second quarter. Northern Trust Corp now owns 934,820 shares of the biotechnology company’s stock valued at $7,516,000 after purchasing an additional 59,558 shares during the last quarter. Institutional investors and hedge funds own 92.09% of the company’s stock.

Shares of PGNX stock traded down $0.17 during trading hours on Friday, reaching $4.56. The stock had a trading volume of 1,642,294 shares, compared to its average volume of 1,378,274. The company has a current ratio of 9.51, a quick ratio of 9.51 and a debt-to-equity ratio of 0.33. Progenics Pharmaceuticals has a 12 month low of $4.47 and a 12 month high of $9.42. The firm has a market capitalization of $392.28 million, a P/E ratio of -5.07 and a beta of 2.67.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.09. Progenics Pharmaceuticals had a negative net margin of 341.78% and a negative return on equity of 66.86%. The company had revenue of $5.32 million during the quarter, compared to analyst estimates of $4.14 million. Sell-side analysts predict that Progenics Pharmaceuticals will post -0.76 EPS for the current year.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.

Read More: What are earnings reports?

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply